These findings suggest that anti-PD-1 treatment affects the frequency of lymphocytes and their intracellular and surface HSP90 expression in r/r cHL lymphoma patients, however, further studies are required to assess the effect of anti-PD-1 treatment on HSP90 expression and localization in bone marrow and peripheral blood lymphocytes. Here, HSP90AA1 is linked to lymphoma.